PLANTATION, Fla., June 2 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company is scheduled to present at the
Informed Investors Biotechnology and Pharmaceutical Stocks Forum at the
Princeton Club in New York City on June 23. The analyst-style forum, which is
to include a presentation from Viragen's President and CEO, Charles A. Rice,
will be webcast following the close of the live event.
"I am looking forward to presenting Viragen's strategy to institutional
investors, not only at this conference, but also in individual meetings which
have been arranged in New York and London this month," stated Mr. Rice. "With
a new financing and recapitalization strategy hopefully completed by mid-June,
these meetings will be important steps for communicating the investment and
growth opportunities that I believe Viragen represents."
Event: Informed Investors Biotechnology and Pharmaceutical Stocks Forum
When: 8:30 a.m. (EDT)
Where: The Princeton Club, 15 West 43rd St. (Between 5th and 6th Avenues)
Fee to attend: $30 (There is no charge for webcast replay)
Keynote Speakers: Lynn Sutherland, President of Sutherland Consulting &
Bill Alpert, Senior Editor and Biotechnology Writer for
Barron's
To register, please visit:
http://www.informedinvestors.com/CustomEvent/85117/index.asp?ForumID=85117
About Viragen, Inc.:
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include natural human alpha interferon, monoclonal
antibodies and a peptide drug. Viragen's strategy also includes the
development of Avian Transgenic Technology as a biomanufacturing platform for
the large-scale, cost-effective production of therapeutic proteins.
Viragen is publicly traded on the American Stock Exchange (VRA).
Viragen's majority owned subsidiary, Viragen International, Inc., is publicly
traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners
and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer
Center, Cancer Research UK, University of Nottingham (U.K.), University of
Miami, America's Blood Centers and the German Red Cross.
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
For more information, please visit: http://www.Viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect", "potential",
"suggests", "may", "will", "should", "could" or similar expressions. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause the actual results to be materially different
from any future results, performance or achievements expressed or implied by
such statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
